Immunocore to Present at Several Investor Conferences in September

Immunocore Holdings plc (Nasdaq: IMCR), a biotechnology company specializing in innovative immunomodulating medicines, will participate in several upcoming investor conferences in September. These presentations will provide key insights into the company's latest developments and strategic directions in the treatment of cancer, infectious diseases, and autoimmune diseases.

At the Cantor Global Healthcare Conference 2026, Immunocore's management will deliver a fireside chat on Thursday, September 10, 2026, at 2:45 p.m. Eastern Daylight Time (EDT). The session will focus on the company’s advancements and future plans. The following day, on Monday, September 14, 2026, management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, also in a fireside chat format at 2:35 p.m. EDT. On Tuesday, September 15, 2026, at 12:15 p.m. EDT, attendees can expect a detailed discussion during the Baird 2026 Global Healthcare Conference.

Additionally, the company will host one-on-one and small group meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026. These meetings will offer more intimate settings for in-depth discussions.

Immunocore’s presentations will be live-streamed and accessible through the ‘Events & Presentations’ section under ‘Events’ in the ‘Investors’ section of the company’s website at www.immunocore.com. Following the events, replays will be available for a limited time.

Immunocore, founded on the development of a novel class of TCR bispecific immunotherapies called ImmTAX, is leveraging its proprietary, flexible platform to create a robust pipeline of treatments for various diseases. One of its most advanced therapies, KIMMTRAK, has received approval in multiple regions for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

"Immunocore is excited to engage with our investor community and share our progress," said Sébastien Desprez, Vice President of Communications at Immunocore. "These conferences provide a valuable opportunity to discuss our strategic initiatives and the potential impact of our therapies on patients worldwide."